Iqirvo PBC denied as non-formulary by Aetna?

Aetna's specific coverage criteria for iqirvo pbc are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Iqirvo (Elafibranor) for PBC as Non-Formulary

Aetna's formulary (drug list) may not include Iqirvo on a covered tier, or may place it at a tier that requires additional authorization. A non-formulary denial does not mean the drug is medically inappropriate — it means Aetna has not yet placed it on its standard list or requires you to justify an exception. As a relatively recently approved therapy for primary biliary cholangitis, Iqirvo may not yet appear on all plan formularies, even though it carries full FDA approval.

## Your Federal Appeal Rights

• ERISA §503: You are entitled to a full-and-fair internal review. Request that the appeal be reviewed by a clinical peer with expertise in hepatology or gastroenterology.
• ACA §2719 external review: If the internal appeal is denied, external review is available. The window is generally four months from the initial denial. Expedited review is available for urgent situations.
• Formulary exception process: Most plans have a formal formulary exception pathway. A non-formulary denial can be converted to a covered exception if you demonstrate that no formulary alternative is clinically appropriate for your specific situation.

## Concrete Appeal Steps

1. Obtain the denial letter and Aetna's formulary exception request form. 2. Identify every formulary alternative Aetna considers in the same drug class or therapeutic category — your prescriber will need to address each one. 3. Have your prescriber document why each formulary alternative is clinically unsuitable for you (contraindicated, previously failed, not FDA-approved for your condition, or otherwise inappropriate per the prescriber's clinical judgment). 4. Submit the formulary exception request alongside a formal internal appeal. 5. Attach the FDA prescribing label and Aetna's own PBC-related Medical Policy.

## Documentation to Gather

• Diagnosis confirmation: Records establishing your PBC diagnosis — AMA serology, imaging, biopsy if applicable, specialist consultation notes.
• Formulary alternative assessment: For each alternative Aetna lists, a prescriber note explaining why it is not appropriate for your case.
• Prior therapy record: Dates, durations, doses, and documented outcomes or intolerances for any previously tried PBC medications.
• Clinical severity documentation: Liver function trend data, imaging or elastography results, and clinical notes characterizing disease progression.
• Prescriber letter: A targeted letter explaining why Iqirvo — and not a formulary substitute — is medically necessary for this patient.

## Criteria-Mapping Structure

Request Aetna's formulary exception criteria in writing. Obtain the FDA prescribing label for Iqirvo. Build a mapping table:

| Exception Criterion | Your Clinical Evidence | |---|---| | [Paste each requirement from Aetna's exception policy] | [Exact documentation from chart, lab, or prescriber letter] |

A direct, criterion-by-criterion rebuttal is far more effective than a narrative letter alone.